Clocortolone
- Atc Codes:D07AB21
- CAS Codes:34097-16-0
- PHARMGKB ID:34097-16-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Germany: Kaban, Kabanimat.
North America
Canada: Cloderm; USA: Cloderm.
Drug combinations
Chemistry
Clocortolone Pivalate: C~27~H~36~ClFO~5~. Mw: 495.02. (1) Pregna-1,4-diene-3,20-dione, 9-chloro-21-(2,2-dimethyl-1-oxopropoxy)-6-fluoro-11-hydroxy-16-methyl-, (6α,11β,16α)-; (2) 9-Chloro-6α-fluoro-11β,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 21-pivalate. CAS-34097-16-0 (1972).
Pharmacologic Category
Skin and Mucous Membrane Agents; Anti-inflammatory Agents. Topical Corticosteroid. (ATC-Code: D07AB21).
Mechanism of action
Stimulates the synthesis of enzymes needed to decrease inflammation, suppress mitotic activity, and cause vasoconstriction.
Therapeutic use
Inflammation of corticosteroid-responsive dermatoses (intermediate-potency topical corticosteroid).
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to clocortolone or any component of the formulation. Viral, fungal, or tubercular skin lesions.
Warnings and precautions
Systemic absorption of topical corticosteroids may cause hypothalamic-pituitary-adrenal axis suppression (reversible), particularly in younger children, which may lead to adrenal crisis. Allergic contact dermatitis can occur. Prolonged treatment with corticosteroids has been associated with the development of Kaposi’s sarcoma. Adverse systemic effects (hyperglycemia, glycosuria, fluid and electrolyte changes, and hypothalamic-pituitary-adrenal axis suppression) may occur when used on large surface areas, for prolonged periods, or with an occlusive dressing. Chronic use of corticosteroids in children may interfere with growth and development.